TITLE

Etanercept plus methotrexate reduced symptoms and disease activity in adult-onset rheumatoid arthritis

AUTHOR(S)
Shoor, Stanford
PUB. DATE
September 2004
SOURCE
ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p42
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article discusses therapeutic effect of the combination of Etanercept (ENC) and Methotrexate (MTX) compared with each treatment alone in patients with Rheumatoid Arthritis (RA). 682 patients > 18 years of age (mean age 53 y, 77% women) who had diagnosed, active adult-onset RA (defined as≥ 10 swollen and≥ 12 painful joints, and≥ 1 of the following: erythrocyte sedimentation rate≥ 28 mm/h, plasma C-reactive protein≥ 20 mg/L, or morning stiffness for≥ 45 min) for 6 months to 20 years (mean disease duration 6.6 y) were investigated. Patients were allocated to ENC (25 mg subcutaneously twice weekly) (n 223), MTX (7.5 mg increased to 20-mg oral capsules once per wk within 8 wk if patients had any painful or swollen joints) (n-228), or ENC plus MTX (combination group, n = 231).
ACCESSION #
14590727

 

Related Articles

  • Etanercept.  // Reactions Weekly;7/28/2007, Issue 1162, p15 

    The article describes the case of a 50-year-old man who developed extensive pulmonary rheumatoid nodules while receiving etanercept for rheumatoid arthritis (RA). The man presented with pain in his left shoulder and a 12-month history of subcutaneous nodules on both arms. The use of etanercept...

  • Etanercept eases productivity losses in rheumatoid arthritis.  // PharmacoEconomics & Outcomes News;9/19/2009, Issue 587, p7 

    The article discusses research which found that etanercept plus methotrexate eases productivity losses at work among patients with rheumatoid arthritis. It references a study by A. Anis et al published in the August 18, 2009 issue of the journal "Rheumatology." Study results showed fewer missed...

  • Agency Says Biologic-Synthetic Mix Works Best For Arthritis. Young, Donna // BioWorld Today;11/26/2007, Vol. 18 Issue 228, p3 

    The article reports on a study by the Agency for Healthcare Research and Quality (AHRQ) which found that combining one synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness in patients with rheumatoid arthritis (RA). AHRQ-funded researchers...

  • The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia. Sulaiman, Wahinuddin; Toib, Ashraful; Chandrashehar, Giriyappanavar; Arshad, Anwar // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p260 

    Objectives: : To evaluate the trends of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis (RA). Methods: Patients who fulfilled the ACR criteria for RA from 1995 to 2006 and who attended the Rheumatology clinic at Ipoh Hospital were selected and their...

  • Pharmacogenetics in Treatment of Rheumatoid Arthritis. Kooloos, W. M.; Huizinga, T. W. J.; Guchelaar, H.-J.; Wessels, J. A. M. // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p164 

    Over the last decades important progress is being made regarding disease modifying anti-rheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). Nevertheless, a substantial part of the patients fail to achieve a good response and/or experience toxicity, which limits further...

  • Combination Therapy for Rheumatoid Arthritis. Walling, Anne D. // American Family Physician;11/1/2004, Vol. 70 Issue 9, p1781 

    Discusses research being done on the therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Reference to a study by L. Klareskog et al published in the February 28, 2004 issue of "Lancet"; Goals of treatment...

  • Infections in biological agents used in rheumatic disease. Byng-Maddick, Rachel; Ehrenstein, Michael // British Journal of Hospital Medicine (17508460);Sep2012, Vol. 73 Issue 9, p517 

    The article discusses the risk of infection associated with the several targeted biological therapies used to treat rheumatoid arthritis (RA). The 5 anti-tumor necrosis factor a (TNF-a) therapies that are currently available are associated with increased risk for tuberculosis and reactivation of...

  • Prior lack of efficacy with etanercept does not predict lack of efficacy with infliximab.  // Formulary;Mar2005, Vol. 40 Issue 3, p93 

    This article reports that a study conducted by researchers at the University of Wisconsin, Stanford University, and several rheumatology clinics across the U.S. found that rheumatoid arthritis patients who do not receive sufficient benefit with etanercept may experience improved disease control...

  • Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Sugioka, Yuko; Inui, Kentaro; Koike, Tatsuya // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2008, Vol. 18 Issue 3, p293 

    Disease-modifying anti-rheumatic drugs (DMARDs) are typically used for the therapy of rheumatoid arthritis (RA), but most have some nephrotoxicity. In several clinical studies, etanercept had fewer adverse effects on renal function than other DMARDs. We report the case of a 64-year-old woman...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics